TNFRSF9 and neoplasm: Elevated expression of T cell activation markers CD25 and CD137, and the production of pro-inflammatory Th1 cytokines IL-2, TNF-α, and IFN-γ, at the tumor site were also consistent with heightened T cell activation when administered after carboplatin (Fig. 4h, i and Supplementary Fig. 3a–d).